Navigation Links
Sundia MediTech Appoints Dr. Chen Chen as Senior VP of Chemistry
Date:7/3/2009

SHANGHAI, July 3 /PRNewswire-Asia/ -- Sundia MediTech, a leading integrated pharmaceutical and biotech R&D outsourcing company in Shanghai, China announced today that Dr. Chen Chen has been appointed Senior Vice President of Chemistry Services.

Prior to joining Sundia, Dr. Chen worked at Neurocrine Biosciences, a drug discovery and development company in San Diego, USA for 15 years, from a staff scientist to Senior Director of Medicinal Chemistry of Neurocrine. In his research and management positions at Neurocrine, Dr. Chen achieved many outstanding scientific and industrial accomplishments, including development of two small molecule antagonists, NBI-42902 and elagolix (aka NBI-56418), of the gonadotropin-releasing hormone receptor into clinical studies. Elagolix, the most advanced in this class, is currently finishing Phase II trials by Neurocrine for the treatment of endometriosis. Dr. Chen designed, synthesized and developed NBI-30775 (R121919), a small molecule antagonist of the corticotrophin-releasing factor receptor as the first-in-class compound advanced into clinical trials for depression/anxiety. Dr. Chen also discovered NBI-31772, the first small molecule inhibitor for the insulin-like growth factor-I/IGF-binding protein. In addition, Dr. Chen identified the first selective antagonist of the melanocortin-5 receptor, and discovered numerous agonists and antagonists for the melanocortin-4 receptor for eating disorders.

Dr. Chen has extensive experience in CNS drug research and GPCRs as drug targets. His knowledge also includes neuropathic pain and metabolic disorders. His research interests extend to clinic and preclinic pharmacokinetics of small molecules and the relationship with their chemical properties.

"It is an honor for Sundia to have world class leading scientists as Dr. Chen in our senior management team. As our clients worldwide are bringing more and more high technical level drug discovery programs to Sundia, Dr. Chen and other scientists at Sundia with excellent track record in drug discovery will make Sundia highly competent to deliver outstanding services to our clients," commented by Dr. Xiaochuan Wang, Chairman and CEO of Sundia.

Dr. Chen received his bachelor's degree in Chemistry from Xiamen University, and his Ph.D. degree from the prestigious Shanghai Institute of Organic Chemistry under the supervision of the late Professor Yao-Zeng Huang, member of the Chinese Academy of Science. He also obtained his postdoctoral training with Professor Sir Derek H. R. Barton, a Nobel Laureate at Texas A&M University in USA. Dr. Chen has so far published near 130 scientific papers in peer-reviewed journals such as J. Am. Chem. Soc., J. Org. Chem., J. Med. Chem., and J. Biol. Chem. He has written numerous review articles on the topics of drug discovery and medicinal chemistry. He is the co-inventor of over 25 US patents. He has been invited to give presentations in numerous scientific conferences such as the Gorden Conference of Medicinal Chemistry and the ACS National Meeting.

About Sundia

Sundia MediTech Company is a leading integrated pharmaceutical contract research organization (CRO) company based in Shanghai, China, to provide R&D outsourcing services to biotech and pharmaceutical companies worldwide, ranging from early hit screening, biological service, lead optimization, DMPK, candidate preclinical development, formulation development, API manufacture, and regulatory submission. For more information, please visit http://www.sundia.com .


'/>"/>
SOURCE Sundia MediTech Company
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Finland Biotech Delegation Visits Sundia
2. CRO Company Sundia Welcomes New Members to Its Executive Team
3. Golden Meditech Announces Financial Year 2008/09 Annual Results
4. Doylestown Hospital and Perot Systems Successfully Implement Advanced MEDITECH 6.0 Platform
5. Sentillion Introduces Advanced Authentication Solution For Direct Access to Cerner, Eclipsys, Epic, McKesson and MEDITECH Applications
6. Golden Meditech Releases FY2008/09 Q3 Results
7. Golden Meditech Brings in Financial Investor Through New Share Issuance
8. Golden Meditech Releases FY2008/09 Interim Results
9. Patient Placement Systems Selects Iatric Systems, Inc. to Deliver Interfaces for MEDITECH Healthcare Information Systems
10. Golden Meditech Increases Stakes in Cordlife, Largest Cord Blood Bank Operator in Southeast Asia
11. Freedom Meditech Receives JumpStart Investment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... 11, 2016 , ... PharmMD CEO Robert Yeager ... focus on contract negotiations, corporate strategy and healthcare data law. Additional responsibilities will ... in data breaches for the Part D Star Rating improvement and Medication Therapy ...
(Date:2/11/2016)... ... February 11, 2016 , ... AccuVein Inc. announces the Infusion ... of Practice, to include vascular visualization as a standard practice. AccuVein ( http://www.accuvein.com ... the market, facilitates adherence to this standard with its easy to use, widely ...
(Date:2/11/2016)... ... February 11, 2016 , ... The annual list showcases the 20 ... DataPoint’s team dedication and commitment to the SharePoint ecosystem. A panel of ... The panel’s goal is to recognize and promote technology entrepreneurship. , The survey ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... and ergoFET force gauges used in physical therapy, occupational therapy and sports medicine ... for resistance cord exercise and therapy, introduces its new microFET Digital Pinch Gauge. ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... results in significantly higher rates of several common cancer screenings, especially among women. ... better outcomes and survival rates. , The study,“What Does Medicaid Expansion Mean ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... -- --> --> Transparency ... titled "Sports Medicine Devices Market - Global Industry Analysis, Size, ... the report, the global sports medicine devices market is anticipated ... growing from a value of US$6.1 bn in 2012 to ... --> The global sports medicine devices market is fueled ...
(Date:2/11/2016)... , Feb. 11, 2016 PLAD, Inc. ... out 2016 with sales exceeding company targets, are adding ... received their trademark from the United States Patent and ... Clark , Chief Executive Officer of PLAD, Inc.  In ... Pennsylvania with two new customers, ...
(Date:2/11/2016)... , Feb. 11, 2016 Exactus ... company providing high-quality specialty pharmacy care for those ... today it has achieved full Specialty Pharmacy Accreditation ... organization dedicated to promoting health care quality through ... --> The URAC accreditation process ...
Breaking Medicine Technology: